{
  "pmcid": "10364863",
  "sha256": "14080bcc2d9fb99b54f2cf51967438631d7030af608fb96f3d15cc4b2af93ec2",
  "timestamp_utc": "2025-11-09T15:07:29.546989+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.037491749174915,
    "reading_ease": 50.25632563256329,
    "word_count": 303
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "The Austrian Breast and Colorectal Cancer Study Group (ABCSG) 8 RCT compared 5 years of tamoxifen with tamoxifen for 2 years followed by anastrozole for 3 years"
      },
      "Participants": {
        "score": 2,
        "evidence": "postmenopausal women with endocrine receptor-positive breast cancer"
      },
      "Intervention": {
        "score": 2,
        "evidence": "compared 5 years of tamoxifen with tamoxifen for 2 years followed by anastrozole for 3 years"
      },
      "Objective": {
        "score": 1,
        "evidence": "The aim of this study was to investigate whether the PAM-50-based 46-gene assay carries prognostic value for risk of local recurrence of breast cancer."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "After a median follow-up of 10.8 years, 23 local events had been observed"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Tumour blocks from 1204 patients who had breast-conserving surgery were available for the PAM-50 analysis"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "1034 of these received radiotherapy"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "0.1 (95 per cent c.i. 0 to 0.7) versus 2.2 (0.9 to 4.6) per cent respectively; subhazard ratio (SHR) 17.18, 95 per cent c.i. 2.06 to 142.88; P =â€‰0.009"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}